Investors

Financials & Filings

Filing date Form Description Filing Group View
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-3

Simplified registration form

Registration Statements
S-3

Simplified registration form

Registration Statements
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

3,4,5
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Proxy Filings

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.